Actinium Pharmaceuticals, Inc.
New York Stock Exchange AmericanTotal Valuation
Actinium Pharmaceuticals, Inc. carries a market capitalization of 36.39M, placing it among publicly traded companies globally. Its enterprise value stands at -9.55M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.39M |
| Enterprise Value | -9.55M |
Share Statistics
Actinium Pharmaceuticals, Inc. currently has 31.37M shares outstanding.
| Shares Outstanding | 31.37M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 345.15, and the price-to-book ratio stands at -0.07.
| PE Ratio | N/A |
| PS Ratio | 345.15 |
| PB Ratio | -0.07 |
| P/TBV Ratio | 13.48 |
| P/FCF Ratio | -1.36 |
| P/OCF Ratio | -1.36 |
Financial Position
Actinium Pharmaceuticals, Inc. maintains a current ratio of 5.89, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.89 |
| Quick Ratio | 5.73 |
| Debt / Equity | 65.93 |
| Debt / EBITDA | -0.06 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -41.15 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Actinium Pharmaceuticals, Inc.'s stock has declined approximately -30.95238% over the past 52 weeks. The 50-day moving average sits at 1.19, while the 200-day moving average is 1.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.95238% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Actinium Pharmaceuticals, Inc. generated 90,000.00 in revenue and converted that into -23.47M in net income, yielding earnings per share of -0.75. EBITDA reached -24.68M, while operating income came in at -25.51M.
| Revenue | 90,000.00 |
| Gross Profit | N/A |
| Operating Income | -25.51M |
| Pretax Income | -23.47M |
| Net Income | -23.47M |
| EBITDA | -24.68M |
| EBIT | -25.51M |
| Earnings Per Share (EPS) | -0.75 |
Balance Sheet
Actinium Pharmaceuticals, Inc. holds 42.13M in cash and equivalents against 1.52M in total debt, resulting in a net debt position of -42.13M. Total book value stands at -415.20M, with working capital of 35.91M providing operational flexibility.
| Cash & Cash Equivalents | 42.13M |
| Total Debt | 1.52M |
| Net Debt | -42.13M |
| Equity (Book Value) | -415.20M |
| Book Value Per Share | -13.30 |
| Working Capital | 35.91M |
Cash Flow
Actinium Pharmaceuticals, Inc. produced -22.88M in operating cash flow over the past twelve months. After subtracting -106,000.00 in capital expenditures, free cash flow totaled -22.98M - equivalent to -0.74 per share.
| Operating Cash Flow | -22.88M |
| Capital Expenditures | -106,000.00 |
| Free Cash Flow | -22.98M |
| FCF Per Share | -0.74 |
Margins
Actinium Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -28,346.67 and net profit margin of -26,078.89 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -28,346.67 |
| Pretax Margin | -26,078.89 |
| Profit Margin | -26,078.89 |
| EBITDA Margin | -27,417.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.70 |
| FCF Yield | -73.30 |
Stock Splits
Actinium Pharmaceuticals, Inc.'s most recent stock split took place on August 11, 2020 with a 30:1 split ratio.
| Last Split Date | 8/11/2020 |
| Split Ratio | 30:1 |
Scores
Actinium Pharmaceuticals, Inc. posts an Altman Z-Score of -13.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.26 |